BRC-201 not checked
Boryung Biopharma Co., Ltd. · TG-1000
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “BRC-201 (pixavir marboxil) 20 mg capsules administered orally as a single dose of 40 mg (2 capsules) for participants weighing less than 80 kg or 80 mg (4 capsules) for participants weighing 80 kg or more.”In the company’s words, NCT07943390 on ClinicalTrials.gov
- Tested for
- Influenza
- Main trialPhase 3
- “This is a Phase 3, multicenter, randomized, double-blind clinical study designed to evaluate the efficacy and safety of BRC-201 in adult and adolescent patients with acute uncomplicated influenza virus infection. The study aims to assess the efficacy of BRC-201 in treating influenza symptoms and to evaluate its safety in patients with influenza.”In the company’s words, NCT07943390 on ClinicalTrials.gov
- Other names
- TG-1000 · Pixavir Marboxil
Other drugs for Influenza
- MRNA-1018-H5Moderna · Phase 3
- Baloxavir MarboxilRoche · Phase 3
- Dipyrone monohydrateBrainfarma Industria Química e Farmacêutica S/A · Phase 3
- CD388Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Phase 3
- MRNA Seasonal Flu vaccineGSK · Phase 3
- GP681Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Phase 3
Coming up1
- Apr 2027Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07943390
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Apr 2027 | A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026